Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.
Also called NCT05440591
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT05440591
-
- Other papers using this trial's data
- First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Singapore
- Registry status
- Unknown status
Technical summary
Registry record NCT05440591. Randomized; no masking; primary purpose treatment. Start 2019-04-01 (actual); primary completion 2023-05-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
- Acronym
- DMVascular
- Condition
- Diabetes
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- MetFORMIN 500 Mg Oral Tablet
- Intervention (Drug)
- Dapagliflozin / metFORMIN Pill
- Lead sponsor
- Tan Tock Seng Hospital
Record details
- Record id
cardio:ct-nct05440591- Content hash
2f95d50537c01f85c80e3a7f90a41c828062bb3c382e965b4f3b6d4eb0d81221